Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 6/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501905 | 1.00 | AHCY (0.73) | AHCYADORA3ADORA2AADORA1PNP | |
| SCHEMBL26381988 | 0.86 | AHCY (0.57) | AHCYADORA3ADORA2AADORA1PNP | |
| SCHEMBL26382000 | 0.84 | AHCY (0.55) | AHCYADORA3ADORA2AADORA1 | |
| SCHEMBL590063 | 0.81 | ADORA2A (0.61) | AHCYADORA3ADORA2AADORA1PNP | |
| SCHEMBL29319896 | 0.80 | PDE4D (0.62) | AHCYADORA3ADORA2AADORA1PNP | |
| Trifluoroacetic Acid SCHEMBL5201752 | 0.80 | AHCY (0.56) | AHCYADORA3ADORA2AADORA1PNP | |
| Trifluoroacetic Acid SCHEMBL242557 | 0.80 | AHCY (0.56) | AHCYADORA3ADORA2AADORA1PNP | |
| Trifluoroacetic Acid SCHEMBL293707 | 0.80 | AHCY (0.56) | AHCYADORA3ADORA2AADORA1PNP | |
| Noraristeromycin SCHEMBL17117186 | 0.80 | AHCY (1.00) | AHCYADORA3 | |
| Noraristeromycin SCHEMBL19644993 | 0.80 | AHCY (1.00) | AHCYADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| CN-113543790-A | Use of A for achieving a fat-reducing effect3Adenosine receptor ligands | 坎-菲特生物药物有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-108367016-B | A3 adenosine receptor ligands for the treatment of ectopic fat accumulation | 坎-菲特生物药物有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-9549943-B2 | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | CAN-FITE BIOPHARMA LTD. (IL) | 2017-01-24 | — | — | US | disclosed |
| US-20150216889-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | CAN-FITE BIOPHARMA LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-8557790-B2 | A3 adenoside receptor agonists for the reduction of intraocular pressure | CAN-FITE BIOPHARMA LTD. (IL) | 2013-10-15 | — | — | US | disclosed |
| US-20120065155-A1 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | CAN-FITE BIOPHARMA LTD. (IL) | 2012-03-15 | — | — | US | disclosed |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-02 | — | — | US | disclosed |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | CAN-FITE BIOPHARMA LTD. (IL) | 2008-12-04 | — | — | US | disclosed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | disclosed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | disclosed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | ADORA3, ADORA2A, ADORA2B | AHCY 432/4885ADORA3 1/4885ADORA2A 2/4885 |
| US-20150216889-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | ADORA3, ADORA2A, ADORA2B | AHCY 618/4885ADORA3 1/4885ADORA2A 2/4885 |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | ADORA3, ADORA2A, ADORA1 | AHCY 198/4885ADORA3 1/4885ADORA2A 2/4885 |
| US-20120065155-A1 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | ADORA3, ADORA1, ADORA2A | AHCY 1800/4885ADORA3 1/4885ADORA2A 3/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | AHCY 714/4885ADORA3 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.